Purpose Of Review: The purpose of the review is to delineate novel approaches for biology-based treatment in advanced gastric cancer. We reviewed the latest translational and clinical research articles and congress presentations.
Recent Findings: A new molecular classification of gastric cancer based on histology, genetic and proteomic alterations has evolved. It provides a roadmap for development of new drugs and combinations and for patient stratification. Anti-HER2 treatment, which is an effective strategy in metastatic gastric cancer, is now also being studied in the perioperative setting. However, resistance mechanisms in advanced disease are poorly understood and optimal patient selection remains challenging. Targeting angiogenesis is an emerging concept in the management of advanced gastric cancer, and ramucirumab has prolonged survival in the second line either as a monotherapy or in combination with paclitaxel. Biomarkers for selecting patients who benefit from ramucirumab are still lacking. Immune checkpoint blockade and inhibition of cancer stemness targets are other emerging directions for the medical treatment of gastric cancer. Large-scale international studies are ongoing.
Summary: Promising biology-based treatment strategies are evolving. But tumor heterogeneity which is an inherent feature of gastric cancer challenges the development of molecularly targeted and personalized treatment strategies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/CCO.0000000000000289 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Letter to Editor regarding comments by Dr. Axer et al. for manuscript weight loss specific to indication, remission of diabetes, and short-term complications after sleeve gastrectomy conversion to Roux-en-Y gastric bypass: a systematic review and meta-analysis.
Surg Obes Relat Dis
February 2025
Department of Surgery and Cancer, Imperial College London, London, United Kingdom.
Poor agreement between biopsies and endoscopic submucosal dissection specimens of Esophageal and Gastric Epithelial Lesions in a western setting.
Dig Liver Dis
March 2025
Endoscopy Unit, Hospital Clínic de Barcelona, Universitat de Barcelona (UB), Barcelona, Spain; Departament de Medicina, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Barcelona, Spain; Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Spain.
Background: Endoscopic forceps biopsy is the primary method for obtaining mucosal tissues, but can lead to false negatives.
Aims: To assess the agreement between endoscopic biopsies and submucosal dissection specimens in esophageal and gastric epithelial lesions and to identify factors associated.
Methods: Cross-sectional study using data from the Spanish national multicenter endoscopic submucosal dissection register.
Current status of endoscopy training for surgeons in Korea: a narrative review.
J Minim Invasive Surg
March 2025
Center for Colorectal Cancer, National Cancer Center, Goyang, Korea.
Flexible gastrointestinal (GI) endoscopy is a fundamental skill in surgical practice, offering both diagnostic and therapeutic capabilities for a wide range of GI diseases. In Korea, the incidence estimates for gastric and colorectal cancers rank among the highest worldwide, underscoring the critical need for well-trained endoscopists. Surgeons play a pivotal role in managing GI diseases, reinforcing the necessity of systematic and comprehensive endoscopic education.
View Article and Find Full Text PDFIn vitro urease inhibition screening of some edible and medicinal herbs to combat Helicobacter pylori related gastric diseases.
Pak J Pharm Sci
March 2025
Department of Pharmacognosy, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan.
Prevalence of gastric diseases caused by Helicobacter Pylori bacteria is very common especially in developing countries. H. pylori is not only responsible for initiating gastric complaints like gastritis and peptic ulcer but may also lead to gastric cancer.
View Article and Find Full Text PDFIntegrating immunotherapy in the treatment of resectable gastric cancer: Are we on the right track?
Med
March 2025
Miguel Servet University Hospital, Medical Oncology Department, 50009 Zaragoza, Spain.
Long et al. evaluated neoadjuvant (NAT) cadonilimab plus FLOT chemotherapy (ChT) in locally advanced gastric (G) and gastroesophageal junction (GEJ) adenocarcinoma, showing a pathological complete response (pCR) rate of 21.1% and an R0 resection rate of 100%.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!